Abstract Number: 2044 • ACR Convergence 2020
Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
Background/Purpose: CD4+ T cells are implicated in the pathogenesis of rheumatoid arthritis (RA) due to strong genetic association with HLA class II alleles, the presence…Abstract Number: 0046 • ACR Convergence 2020
Socioeconomic Disparities in Functional Status Among RA Patients: A Longitudinal Analysis Using RISE Data
Background/Purpose: Prior studies have shown that RA outcomes, including disease activity, erosions, and disability, are worse among patients with low socioeconomic status (SES). However, few…Abstract Number: 0135 • ACR Convergence 2020
Understanding the Rheumatologist-Patient Relationship in Treating Rheumatoid Arthritis
Background/Purpose: Understanding patient satisfaction with their rheumatologist and the drivers of satisfaction is crucial to improving doctor-patient interactions, helping patients get on the right treatment…Abstract Number: 0160 • ACR Convergence 2020
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Background/Purpose: The Patient-Reported Outcome Measure Information System (PROMIS) includes a set of instruments developed to measure physical, mental and social health. PROMIS measures have been…Abstract Number: 0192 • ACR Convergence 2020
Influence of Inflammatory and Non-inflammatory Rheumatic Disorders on the Clinical and Biological Profile of Adult-onset Diabetes
Background/Purpose: To compare the profile of adult-onset diabetes in patients with rheumatoid arthritis (RA) or osteoarthritis (OA), two chronic diseases leading to disability differing by…Abstract Number: 0208 • ACR Convergence 2020
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results
Background/Purpose: Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 (JAK1) inhibitor. FINCH 1 (NCT02889796) assessed FIL efficacy and safety in patients (pts) with…Abstract Number: 0225 • ACR Convergence 2020
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…Abstract Number: 0241 • ACR Convergence 2020
A Prospective Analysis of Factors Impacting Medication Adverse Events in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA), a chronic autoimmune disease affecting approximately 1.5 million people in the U.S., is characterized by inflammation of the synovial tissues with…Abstract Number: 0485 • ACR Convergence 2020
Non-obese Rheumatoid Arthritis Patients with Low Low-density Lipoprotein Have Higher Coronary Atherosclerosis Burden, Greater Plaque Progression and Cardiovascular Event Risk
Background/Purpose: RA patients with low body weight incur higher mortality than obese patients. Paradoxically, RA patients in the lowest low-density lipoprotein group (LDL < 70…Abstract Number: 0585 • ACR Convergence 2020
Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Background/Purpose: The “Joint Resources – Sedentary Behaviour” randomised controlled trial (RCT) (1,2,3) aimed to reduce sedentary behaviour in patients with rheumatoid arthritis (RA) by means…Abstract Number: 0750 • ACR Convergence 2020
Nuclei Detection in Rheumatoid Arthritis Synovial Tissue Using Artificial Intelligence
Background/Purpose: Hematoxylin and eosin (H&E) stained rheumatoid arthritis synovium are routinely used to assess inflammation [1]. In this work, we propose an automated approach using…Abstract Number: 0767 • ACR Convergence 2020
Anti-acetylated Protein Antibodies in Rheumatoid Arthritis (RA): Clues for the Starting Point of Autoantibody Responses in RA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies such as rheumatoid factor (RF) and anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-carbamylated…Abstract Number: 0784 • ACR Convergence 2020
Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis
Background/Purpose: The study aimed to investigate the expression and clinical significance of Tyro3TK on CD14+CD16+ and CD14+CD16- monocyte subsets and explore the effect of Tyro3TK…Abstract Number: 0801 • ACR Convergence 2020
The Comparative Effectiveness of Abatacept versus TNF Inhibitors in Patients Who Are ACPA Positive and Have the Shared Epitope: Results from a US National Observational Study
Background/Purpose: The HLA-DRB1 shared epitope (SE) is associated with joint destruction in ACPA+ patients (pts) with RA.1 In the Early AMPLE trial, among ACPA+ pts…Abstract Number: 0817 • ACR Convergence 2020
Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Background/Purpose: JAK inhibitors (JAKi) are targeted synthetic DMARDs (tsDMARDs) with a different mode of action (MOA) to conventional synthetic and biologic DMARDs (cs and bDMARDs).…
- « Previous Page
- 1
- …
- 158
- 159
- 160
- 161
- 162
- …
- 188
- Next Page »